Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt的子公司Adimune成功完成其免疫调节治疗Adi平台的临床前疗效和安全性研究,迈向首次人体临床试验
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt的子公司Adimune成功完成其免疫调节治疗Adi平台的临床前疗效和安全性研究,迈向首次人体临床试验
使用浏览器的分享功能,分享给你的好友吧